X4 Pharmaceuticals, Inc Quarterly Operating Income (Loss) in USD from Q1 2017 to Q2 2024

Taxonomy & unit: us-gaap: USD
Description: The net result for the period of deducting operating expenses from operating revenues.
Summary: X4 Pharmaceuticals, Inc quarterly/annual Operating Income (Loss) history and growth rate from Q1 2017 to Q2 2024.
X4 Pharmaceuticals, Inc Operating Income (Loss) for the quarter ending June 30, 2024 was $71.1M.
X4 Pharmaceuticals, Inc Operating Income (Loss) for the twelve months ending June 30, 2024 was -$18.6M, a 81.6% increase year-over-year.
X4 Pharmaceuticals, Inc annual Operating Income (Loss) for 2023 was -$108M, a 22.8% decline from 2022.
X4 Pharmaceuticals, Inc annual Operating Income (Loss) for 2022 was -$87.6M, a 2.89% decline from 2021.
X4 Pharmaceuticals, Inc annual Operating Income (Loss) for 2021 was -$85.1M, a 42.1% decline from 2020.

Operating Income (Loss), Trailing 12 Months (USD)

Operating Income (Loss), Quarterly (USD)

Operating Income (Loss), YoY Quarterly Growth (%)

Period	TTM Value	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed
Q2 2024	-$18.6M	$71.1M	+$96.9M		Apr 1, 2024	Jun 30, 2024	10-Q	2024-08-08
Q1 2024	-$116M	-$37.3M	-$7.99M	-27.2%	Jan 1, 2024	Mar 31, 2024	10-Q	2024-05-07
Q4 2023	-$108M	-$25.2M	+$378K	+1.48%	Oct 1, 2023	Dec 31, 2023	10-K	2024-03-21
Q3 2023	-$108M	-$27.2M	-$7.06M	-35%	Jul 1, 2023	Sep 30, 2023	10-Q	2023-11-09
Q2 2023	-$101M	-$25.8M	-$5.24M	-25.5%	Apr 1, 2023	Jun 30, 2023	10-Q	2024-08-08
Q1 2023	-$95.6M	-$29.3M	-$8.04M	-37.8%	Jan 1, 2023	Mar 31, 2023	10-Q	2024-05-07
Q4 2022	-$87.6M	-$25.6M	+$3.48M	+12%	Oct 1, 2022	Dec 31, 2022	10-K	2024-03-21
Q3 2022	-$91M	-$20.2M	-$1.04M	-5.41%	Jul 1, 2022	Sep 30, 2022	10-Q	2023-11-09
Q2 2022	-$90M	-$20.6M	-$1.57M	-8.28%	Apr 1, 2022	Jun 30, 2022	10-Q	2023-08-10
Q1 2022	-$88.4M	-$21.3M	-$3.33M	-18.6%	Jan 1, 2022	Mar 31, 2022	10-Q	2023-05-04
Q4 2021	-$85.1M	-$29.1M	-$11.4M	-64.6%	Oct 1, 2021	Dec 31, 2021	10-K	2024-03-21
Q3 2021	-$73.7M	-$19.1M	-$2.14M	-12.6%	Jul 1, 2021	Sep 30, 2021	10-Q	2022-11-03
Q2 2021	-$71.6M	-$19M	-$4.34M	-29.6%	Apr 1, 2021	Jun 30, 2021	10-Q	2022-08-04
Q1 2021	-$67.2M	-$17.9M	-$7.36M	-69.5%	Jan 1, 2021	Mar 31, 2021	10-Q	2022-05-12
Q4 2020	-$59.9M	-$17.7M	-$6.78M	-62.3%	Oct 1, 2020	Dec 31, 2020	10-K	2023-03-21
Q3 2020	-$53.1M	-$17M	-$4K	-0.02%	Jul 1, 2020	Sep 30, 2020	10-Q	2021-11-04
Q2 2020	-$53.1M	-$14.7M	-$1.24M	-9.27%	Apr 1, 2020	Jun 30, 2020	10-Q	2021-08-03
Q1 2020	-$51.8M	-$10.6M	-$143K	-1.37%	Jan 1, 2020	Mar 31, 2020	10-Q	2021-05-06
Q4 2019	-$51.7M	-$10.9M	-$2.82M	-35%	Oct 1, 2019	Dec 31, 2019	10-K	2022-03-17
Q3 2019	-$48.9M	-$17M	-$8.43M	-98.7%	Jul 1, 2019	Sep 30, 2019	10-Q	2020-11-05
Q2 2019	-$40.5M	-$13.4M	-$7.04M	-110%	Apr 1, 2019	Jun 30, 2019	10-Q	2020-08-04
Q1 2019	-$33.4M	-$10.4M	-$4.33M	-70.8%	Jan 1, 2019	Mar 31, 2019	10-Q	2020-05-07
Q4 2018	-$29.1M	-$8.05M	-$10.3M	-453%	Oct 1, 2018	Dec 31, 2018	10-K	2021-03-19
Q3 2018	-$18.8M	-$8.55M	+$4.51M	+34.6%	Jul 1, 2018	Sep 30, 2018	10-Q	2019-11-07
Q2 2018	-$23.3M	-$6.38M	-$732K	-13%	Apr 1, 2018	Jun 30, 2018	10-Q	2019-08-07
Q1 2018	-$22.5M	-$6.11M	-$283K	-4.86%	Jan 1, 2018	Mar 31, 2018	10-Q	2019-05-15
Q4 2017	-$22.2M	$2.28M			Oct 1, 2017	Dec 31, 2017	10-K	2020-03-12
Q3 2017		-$13.1M			Jul 1, 2017	Sep 30, 2017	10-Q	2018-11-09
Q2 2017		-$5.64M			Apr 1, 2017	Jun 30, 2017	10-Q	2018-08-13
Q1 2017		-$5.83M			Jan 1, 2017	Mar 31, 2017	10-Q	2018-05-10

* An asterisk sign (*) next to the value indicates that the value is likely invalid.